Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential.

Gan L, Yang Y, Li Q, Feng Y, Liu T, Guo W. · 2018

Read Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. by Gan L, Yang Y, Li Q, Feng Y, Liu T, Guo W. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5845366.txt.

Description

Gan and co-authors review EZH2, an enzyme that silences genes by marking histones. Their review appeared in Biomarker Research. EZH2 is the engine of the PRC2 complex. It lays down a triple methyl tag that switches genes off.

Many cancers carry far too much of it. The excess feeds growth, invasion, and drug resistance. In a few cancers the same enzyme holds tumors back instead. It also shapes the immune cells that patrol tumors. Blockers now in trials aim to release its grip on gene control. The review also gathers what regulates the enzyme itself across cancers.

Catalog record

CREATORGan L, Yang Y, Li Q, Feng Y, Liu T, Guo W.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE56 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5845366

Browse the full library · About the Tower of Babel